S&P・Nasdaq 本質的価値 お問い合わせ

MAIA Biotechnology, Inc. MAIA NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

MAIA Biotechnology, Inc. (MAIA) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.

アナリスト予想 一株当たり利益(EPS) $-1.49 および 売上高 $0.00B 来期予想.

一株当たり利益(EPS)実績推移: 2024: 実績 $-1.05 vs 予想 $-1.49 (上回る +29.3%). 2025: 実績 $-0.70 vs 予想 $-0.74 (上回る +5.4%). アナリスト精度: 76%.

EPS予測 — MAIA

76%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024 Actual –$1.05 vs Est –$1.49 ▲ 41.4% off
2025 Actual –$0.70 vs Est –$0.74 ▲ 5.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

売上高予測 — MAIA

Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
お問い合わせ
🎓
SharesGrow アカデミー
本質的価値の計算と割安株の見つけ方を学ぶ。
毎週のライブセッション
メッセージを送る